看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | 40.7x - 45.0x | 42.9x |
| Selected Fwd P/E Multiple | 26.0x - 28.7x | 27.4x |
| Fair Value | €51.77 - €57.22 | €54.49 |
| Upside | -16.1% - -7.3% | -11.7% |
| Benchmarks | - | Full Ticker |
| Xeris Biopharma Holdings, Inc. | - | NasdaqGS:XERS |
| Amphastar Pharmaceuticals, Inc. | - | NasdaqGS:AMPH |
| Jazz Pharmaceuticals plc | - | NasdaqGS:JAZZ |
| Organon & Co. | - | NYSE:OGN |
| Viatris Inc. | - | NasdaqGS:VTRS |
| Corcept Therapeutics Incorporated | - | DB:HTD |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| XERS | AMPH | JAZZ | OGN | VTRS | HTD | |||
| NasdaqGS:XERS | NasdaqGS:AMPH | NasdaqGS:JAZZ | NYSE:OGN | NasdaqGS:VTRS | DB:HTD | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | 26.7% | 1.4% | -23.5% | NM- | 8.2% | ||
| 3Y CAGR | NM- | 36.9% | NM- | -13.8% | NM- | 7.5% | ||
| Latest Twelve Months | 46.3% | -19.1% | -202.5% | -30.0% | -436.5% | 5.6% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -157.6% | 15.5% | 2.8% | 18.1% | -2.7% | 25.3% | ||
| Prior Fiscal Year | -38.0% | 21.3% | 10.8% | 16.3% | 0.4% | 21.9% | ||
| Latest Fiscal Year | -27.0% | 21.8% | 13.8% | 13.5% | -4.3% | 20.7% | ||
| Latest Twelve Months | -13.0% | 18.6% | -9.9% | 11.1% | -24.6% | 18.4% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 155.6x | 6.5x | 6.6x | 6.7x | 6.1x | 69.1x | ||
| Price / LTM Sales | 4.5x | 1.5x | 1.7x | 0.4x | 0.8x | 10.6x | ||
| LTM P/E Ratio | -34.5x | 8.2x | -16.7x | 3.4x | -3.3x | 57.6x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -34.5x | -3.3x | 8.2x | |||||
| Historical LTM P/E Ratio | 18.7x | 27.8x | 37.6x | |||||
| Selected P/E Multiple | 40.7x | 42.9x | 45.0x | |||||
| (x) LTM Net Income | 132 | 132 | 132 | |||||
| (=) Equity Value | 5,375 | 5,658 | 5,941 | |||||
| (/) Shares Outstanding | 105.4 | 105.4 | 105.4 | |||||
| Implied Value Range | 51.01 | 53.70 | 56.38 | |||||
| FX Rate: USD/EUR | 1.2 | 1.2 | 1.2 | Market Price | ||||
| Implied Value Range (Trading Cur) | 43.81 | 46.12 | 48.42 | 61.70 | ||||
| Upside / (Downside) | -29.0% | -25.3% | -21.5% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | XERS | AMPH | JAZZ | OGN | VTRS | HTD | |
| Value of Common Equity | 1,105 | 1,107 | 6,751 | 2,397 | 11,309 | 7,569 | |
| (/) Shares Outstanding | 161.5 | 46.5 | 60.7 | 260.0 | 1,165.9 | 105.4 | |
| Implied Stock Price | 6.84 | 23.81 | 111.30 | 9.22 | 9.70 | 71.84 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.16 | |
| Implied Stock Price (Trading Cur) | 6.84 | 23.81 | 111.30 | 9.22 | 9.70 | 61.70 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.16 | |